Cardiff Oncology Receives FDA Orphan Drug Designation for Onvansertib in Chronic Myelomonocytic Leukemia

Cardiff Oncology, Inc. has received Orphan Drug Designation from the FDA for its lead drug candidate, onvansertib, aimed at treating chronic myelomonocytic leukemia (CMML). This designation will facilitate the development of treatments for this rare disease, offering potential benefits like tax credits for clinical testing and market exclusivity. The company emphasizes the significant unmet medical need for CMML patients due to the limited existing treatment options.